VP attenuated YAP and TAZ levels following TGF-β1 stimulation and reduced fibrosis markers, suggesting its potential as a therapeutic agent for liver fibrosis [36]. The gene discussed is TAFAZZIN; the disease is Hepatic fibrosis.